Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
regarding our study on the evolution of metabolic dysfunction-associated steatotic liver disease (MASLD) and its impact on hepatocellular carcinoma (HCC) risk. 2 Their analysis comparing MASLD and metabolic-associated fatty liver disease (MAFLD) outcomes provides valuable additional perspectives.Wang et al. 1 found that the MASLD-only group had a higher adjusted hazard ratio (aHR) for liver-related outcomes compared to the MAFLD-only group (3.22 vs. 2.65).This difference may stem from MAFLD criteria including overweight individuals with hepatic steatosis but no cardiometabolic risk factors, who do not meet MASLD criteria.Further investigation is needed to confirm this finding.Our previous work showed MASLD, MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD) were each associated with increased risk of liver-related events in fully adjusted models.However, intrahepatic cholangiocarcinoma risk did not significantly differ among steatotic liver disease (SLD) subtypes.3 Future research should incorporate a non-SLD cohort (individuals without hepatic steatosis) as a reference and compare MAFLD subtypes (overweight or obesity, type 2 diabetes mellitus, and two or more metabolic risk factors) against SLD subtypes (MASLD, Met-ALD, and ALD) to elucidate their prognostic implications on